Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -3% Improvement Relative Risk Auld et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 217 patients in the USA No significant difference in mortality Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457 Favors HCQ Favors control
ICU and ventilator mortality among critically ill adults with COVID-19
Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457
Auld et al., ICU and ventilator mortality among critically ill adults with COVID-19, Critical Care Medicine, doi:10.1097/ccm.0000000000004457
Apr 2020   Source   PDF  
  All Studies   Meta
Retrospective 217 critically ill patients, 114 receiving HCQ, showing no significant difference in mortality.
risk of death, 2.8% higher, RR 1.03, p = 1.00, treatment 33 of 114 (28.9%), control 29 of 103 (28.2%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Auld et al., 26 Apr 2020, retrospective, USA, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Online Brief Reports ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019* Sara C. Auld, MD, MSc1–3; Mark Caridi-Scheible, MD1,4; James M. Blum, MD1,4,5,6; Chad Robichaux, MPH5,6; Colleen Kraft, MD, MSc7,8; Jesse T. Jacob, MD, MSc3,7; Craig S. Jabaley, MD1,4; David Carpenter, PA1; Roberta Kaplow, PhD, RN9; Alfonso C. Hernandez-Romieu, MD, MPH7; Max W. Adelman, MD7; Greg S. Martin, MD, MSc1,2,6; Craig M. Coopersmith, MD1,10; David J. Murphy, MD, PhD1,2,11; and the Emory COVID-19 Quality and Clinical Research Collaborative Objectives: To determine mortality rates among adults with critical illness from coronavirus disease 2019. Design: Observational cohort study of patients admitted from March 6, 2020, to April 17, 2020. Setting: Six coronavirus disease 2019 designated ICUs at three hospitals within an academic health center network in Atlanta, Georgia, United States. Patients: Adults greater than or equal to 18 years old with confirmed severe acute respiratory syndrome-CoV-2 disease who were admitted to an ICU during the study period. Interventions: None. Measurements and Main Results: Among 217 critically ill patients, mortality for those who required mechanical ventilation was 35.7% (59/165), with 4.8% of patients (8/165) still on the ventilator at the time of this report. Overall mortality to date in this critically ill cohort is 30.9% (67/217) and 60.4% (131/217) patients have survived to hospital discharge. Mortality was significantly associ- *See also p. 1398. 1 Emory Critical Care Center (ECCC), Atlanta, GA. 2 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA. 3 Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA. 4 Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA. 5 Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA. 6 Georgia Clinical and Translational Science Alliance (CTSA), Atlanta, GA. 7 Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA. 8 Department of Pathology, Emory University School of Medicine, Atlanta, GA. 9 Emory University Hospital, Emory Healthcare, Atlanta, GA. 10 Department of Surgery, Emory University School of Medicine, Atlanta, GA. 11 Office of Quality and Risk, Emory Healthcare, Atlanta, GA. Copyright © 2020 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved. DOI: 10.1097/CCM.0000000000004457 Critical Care Medicine ated with older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure Assessment score, lower Pao2/ Fio2 ratio, higher d-dimer, higher C-reactive protein, and receipt of mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy. Conclusions: Despite multiple reports of mortality rates exceeding 50% among critically ill adults with coronavirus disease 2019, particularly among those requiring mechanical ventilation, our early experience indicates that many patients survive their critical illness. (Crit Care Med 2020; 48:e799–e804) Key Words: coronavirus; critical care; intubation; mortality; respiration, artificial; respiratory distress..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop